{"doc_id": "si-2025-0353-reg-1", "parent_doc_id": "si-2025-0353", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 353 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) Regulations 2025. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2025” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) regulation 2025 (2) collective citation medicinal product (prescription control supply) regulation 2003 2025 includes regulation", "start_char": 729, "end_char": 1011, "source_path": "downloads\\2025\\2025_0353.pdf", "extraction_method": "pdfminer", "checksum": "sha256:87d6f057d692dee3ae12e8cfb7ac353bba84ba330e2cc544b7b084f99878fbb4", "cross_refs": []}
{"doc_id": "si-2025-0353-reg-2", "parent_doc_id": "si-2025-0353", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 353 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "In these Regulations –", "text_raw": "2. \n\nIn these Regulations – \n\n“Principal Regulations” means the Medicinal Products (Prescription and Control \nof Supply) Regulations 2003 ( S.I. No. 540 of 2003); \n\n“Regulations of 2024” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 5) Regulations 2024 (S.I. No. 582 of 2024). \n\nThe Twelfth Schedule (as amended by Regulation 3 of the Regulations of 2024) \nto the Principal Regulations is amended by inserting the following entry: \n\n“ \n\nMedicinal \nproduct \n\nColumn 1 \nNirsevimab \n\nRoute of \nadministration \n\nColumn 3 \nIntramuscular \n(IM) injection. \n\nForm and \npresentation of \nproduct \nadministered \n\nColumn 2 \n50mg in 0.5mL \npre-filled \nsyringe; 100mg \nin 1mL prefilled syringe. \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \nColumn 4 \n\nPassive \nimmunisation \nwith \nnirsevimab of \nall infants who \nare born during \nthe RSV \nseason. \n\nPassive \nimmunisation \nwith \nnirsevimab of \nall *high-risk \ninfants aged \n≤12 months at \nthe start of their \n\nDosage and \nconditions of \nadministration \n\nColumn 5 \nIn accordance with \nthe summary of \nproduct \ncharacteristics and \nthe relevant \nrecommendations \nor guidelines issued \nby the National \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for Health. \n\nInfants weight<5kg: \nA single dose of \n50mg (0.5ml) \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 25th July, 2025. \n\n \n \n \n \n \n\f[353] 3 \n\nfirst RSV \nseason. \n\nadministered \nintramuscularly. \n\nInfants weight≥ \n5kg: A single dose \nof 100mg (1.0ml) \nadministered \nintramuscularly. \n\nChildren up to 24 \nmonths entering \ntheir second season: \n200 mg given as 2 x \n100 mg \nintramuscular \ninjections. \n\nPassive \nimmunisation \nwith \nnirsevimab of \nall infants who \nare aged ≤6 \nmonths at the \nstart of the \nRSV season. \n\nPassive \nimmunisation \nwith \nnirsevimab of \nall ex-preterm \ninfants under \n24 months of \nage with \nChronic Lung \nDisease in their \nsecond RSV \nseason. \n\n ”. \n\nGIVEN under my Official Seal, \n\n22 July, 2025. \n\nJENNIFER CARROLL MACNEILL, \n\nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f4 [353]", "text_norm": "2 regulation - principal regulation mean medicinal product (prescription control supply) regulation 2003 ( s.i no 540 2003) regulation 2024 mean medicinal product (prescription control supply) (amendment) (no 5) regulation 2024 (s.i no 582 2024) twelfth schedule (as amended regulation 3 regulation 2024) principal regulation amended inserting following entry medicinal product column 1 nirsevimab route administration column 3 intramuscular (im) injection form presentation product administered column 2 50mg 0.5ml pre-filled syringe 100mg 1ml prefilled syringe indication medicinal product may administered column 4 passive immunisation nirsevimab infant born rsv season passive immunisation nirsevimab high-risk infant aged 12 month start dosage condition administration column 5 accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health infant weight 5kg single dose 50mg (0.5ml) notice making statutory instrument published iris oifigiuil 25th july 2025 353 3 first rsv season administered intramuscularly infant weight 5kg single dose 100mg (1.0ml) administered intramuscularly child 24 month entering second season 200 mg given 2 x 100 mg intramuscular injection passive immunisation nirsevimab infant aged 6 month start rsv season passive immunisation nirsevimab ex-preterm infant 24 month age chronic lung disease second rsv season  given official seal 22 july 2025 jennifer carroll macneill minister health 4 353", "start_char": 1011, "end_char": 3154, "source_path": "downloads\\2025\\2025_0353.pdf", "extraction_method": "pdfminer", "checksum": "sha256:87d6f057d692dee3ae12e8cfb7ac353bba84ba330e2cc544b7b084f99878fbb4", "cross_refs": []}
{"doc_id": "si-2025-0353-explanatory-note", "parent_doc_id": "si-2025-0353", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 353 of 2025", "title": "section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No.", "year": 2025, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to update the schedule of medicinal products \nwhich may be supplied and administered pursuant to Regulation 4F of the \nMedicinal Products (Prescription and Control of Supply) Regulations 2003. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) Regulations 2025. \n\n \n \n \n \n \n\f[353] 5 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-597) 30. 7/25. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation update schedule medicinal product may supplied administered pursuant regulation 4f medicinal product (prescription control supply) regulation 2003 regulation may cited medicinal product (prescription control supply) (amendment) regulation 2025 353 5 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-597) 30 7 25 propylon", "start_char": 3154, "end_char": 4236, "source_path": "downloads\\2025\\2025_0353.pdf", "extraction_method": "pdfminer", "checksum": "sha256:87d6f057d692dee3ae12e8cfb7ac353bba84ba330e2cc544b7b084f99878fbb4", "cross_refs": []}
